The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
GAD Treatment and Insulin Secretion in Recent-Onset Type 1 Diabetes
Open accessAbstract
BACKGROUND: The 65-kD isoform of glutamic acid decarboxylase (GAD) is a major autoantigen in patients with type 1 diabetes mellitus. This trial assessed the ability of alum-formulated GAD (GAD-alum) to reverse recent-onset type 1 diabetes in patients 10 to 18 years of age. METHODS: We randomly assigned 70 patients with type 1 diabetes who had fasting C-peptide levels above 0.1 nmol per liter (0.3 ng per milliliter) and GAD autoantibodies, recruited within 18 months after receiving the diagnosis of diabetes, to receive subcutaneous injections of 20 microg of GAD-alum (35 patients) or placebo (alum alone, 35 patients) on study days 1 and 30. At day 1 and months 3, 9, 15, 21, and 30, patients underwent a mixed-meal tolerance test to stimulate residual insulin secretion (measured as the C-peptide level). The effect of GAD-alum on the immune system was also studied. RESULTS: Insulin secretion gradually decreased in both study groups. The study treatment had no significant effect on change in fasting C-peptide level after 15 months (the primary end point). Fasting C-peptide levels declined from baseline levels significantly less over 30 months in the GAD-alum group than in the placebo group (-0.21 vs. -0.27 nmol per liter [-0.62 vs. -0.81 ng per milliliter], P=0.045), as did stimulated secretion measured as the area under the curve (-0.72 vs. -1.02 nmol per liter per 2 hours [-2.20 vs. -3.08 ng per milliliter per 2 hours], P=0.04). No protective effect was seen in patients treated 6 months or more after receiving the diagnosis. Adverse events appeared to be mild and similar in frequency between the two groups. The GAD-alum treatment induced a GAD-specific immune response. CONCLUSIONS: GAD-alum may contribute to the preservation of residual insulin secretion in patients with recent-onset type 1 diabetes, although it did not change the insulin requirement. (ClinicalTrials.gov number, NCT00435981.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GAD₆₅based therapies delivered via subcutaneous or intralymphatic administration have been tested in multiple clinical trials.[24][25][26] Overall efficacy in preserving insulin secretion was not shown.”
From The future of type 1 diabetes therapy (2025) · cites this paper as [24]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
What's wrong with Bonferroni adjustments
Perneger, T. V. (1998) · BMJ · doi:10.1136/bmj.316.7139.1236 · Cited by 5,900
Type 1 diabetes: new perspectives on disease pathogenesis and treatment
Atkinson, M. A., & Eisenbarth, G. S. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05415-0 · Cited by 1,491
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043980 · Cited by 1,099
Steffes, M. W., Sibley, S., Jackson, M., & Thomas, W. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.832 · Cited by 695
Herold, K. C., Gitelman, S. E., Masharani, U. B., Hagopian, W., Bisikirska, B. C., DONALDSON, D. L., Rother, K. I., Diamond, B. E., Harlan, D. M., & Bluestone, J. A. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1763 · Cited by 641
Bækkeskov, S., Nielsen, J. H., Marner, B., Bilde, T., Ludvigsson, J., & Lernmark, Å. (1982) · Nature · doi:10.1038/298167a0 · Cited by 530
Self-citationRaz, I., Elias, D., Avron, A., Tamir, M., Metzger, M., & Cohen, I. R. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06801-5 · Cited by 508
Randomisation and baseline comparisons in clinical trials
Altman, D. G., & Doré, C. J. (1990) · The Lancet · doi:10.1016/0140-6736(90)90014-v · Cited by 508
White, N. H., Cleary, P. A., Dahms, W. T., Goldstein, D. E., Malone, J. K., & Tamborlane, W. V. (2001) · The Journal of Pediatrics · doi:10.1067/mpd.2001.118887 · Cited by 458
Research works printed but not linked: 3
- Dupre J, 1988, Diabetes Care, 11, 37
- Eisenbarth GS, 1985, Diabetes Res, 2, 271
- Daneman D, 1987, Clin Invest Med, 10, 484
Cited by
Sorted by citations
Atkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60591-7 · Cited by 2,931
Katsarou, A., Gudbjörnsdottir, S., Rawshani, A., Dabelea, D., Bonifacio, E., Anderson, B. J., Jacobsen, L. M., Schatz, D. A., & Lernmark, Å. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.16 · Cited by 1,475
Genetics, pathogenesis and clinical interventions in type 1 diabetes
Bluestone, J. A., Herold, K., & Eisenbarth, G. (2010) · Nature · doi:10.1038/nature08933 · Cited by 1,265
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function
Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904452 · Cited by 1,093
Type 1 Diabetes: Etiology, Immunology, and Therapeutic Strategies
Van Belle, T. L., Coppieters, K. T., & Von Herrath, M. G. (2011) · Physiological Reviews · doi:10.1152/physrev.00003.2010 · Cited by 1,022
Metadata
- Authors
- Ludvigsson, J., Faresjö, M., Hjorth, M., Axelsson, S., Chéramy, M., Pihl, M., Vaarala, O., Forsander, G., Ivarsson, S., Johansson, C., Lindh, A., Nilsson, N.-Ö., Åman, J., Örtqvist, E., Zerhouni, P., & Casas, R.
- Affiliations
- Linköping University (SE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-10-30
- Volume
- 359
- Issue
- 18
- Pages
- 1909-1920
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2041637201
- Cited by
- 520
- References
- 32
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 13 · 2023: 13 · 2022: 15 · 2021: 16 · 2020: 21 · 2019: 10 · 2018: 14 · 2017: 12 · 2016: 26 · 2015: 20 · 2014: 28 · 2013: 55 · 2012: 51
- FWCI
- 38.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- type 1 diabetes, glutamic acid decarboxylase, glutamic acid decarboxylase antibodies, residual insulin secretion, C-peptide, recent-onset diabetes, autoimmunity, mixed meal tolerance test
- MeSH terms
- Insulin Secretion, Adolescent, Analysis of Variance, Autoantibodies, C-Peptide, Child, Diabetes Mellitus, Type 1, Female, Glutamate Decarboxylase, Humans, Hypoglycemic Agents, Immunotherapy, Injections, Subcutaneous, Insulin, Male
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
